Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
COGT Cogent Biosciences	$11.50 +3.7%	$6.78	$3.72 ▼ $12.61	$1.26B	1.88	1.59 million shs	3.63 million shs
EPRX Eupraxia Pharmaceuticals	$5.35 -4.3%	$4.39	$2.20 ▼ $6.20	$201M	1.55	13,447 shs	3,393 shs
IMNM Immunome	$8.40 -1.3%	$8.67	$5.15 ▼ $16.81	$740.47M	1.92	902,919 shs	984,556 shs
LENZ LENZ Therapeutics	$32.75 -2.9%	$29.78	$16.54 ▼ $38.93	$949.37M	0.42	196,637 shs	462,639 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
COGT Cogent Biosciences	+3.70%	+17.59%	+62.43%	+169.32%	+24.32%
EPRX Eupraxia Pharmaceuticals	-4.31%	-4.31%	+38.58%	+68.74%	+99.59%
IMNM Immunome	-1.29%	-1.75%	-8.70%	+17.15%	-40.68%
LENZ LENZ Therapeutics	-2.91%	+4.43%	+12.93%	+42.02%	+50.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
COGT Cogent Biosciences	3.5474 of 5 stars	4.4	3.0	3.0	1.7	0.6
EPRX Eupraxia Pharmaceuticals	2.3855 of 5 stars	3.6	2.0	2.0	0.0	0.6
IMNM Immunome	1.9992 of 5 stars	3.5	0.0	3.6	2.5	0.0
LENZ LENZ Therapeutics	1.3172 of 5 stars	3.6	0.0	2.3	0.8	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
COGT Cogent Biosciences	2.82	Moderate Buy	$18.00	56.52% Upside
EPRX Eupraxia Pharmaceuticals	3.20	Buy	$11.00	105.65% Upside
IMNM Immunome	3.00	Buy	$23.33	177.78% Upside
LENZ LENZ Therapeutics	3.17	Buy	$46.60	42.29% Upside

Current Analyst Ratings Breakdown

Latest EPRX, LENZ, COGT, and IMNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/8/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $22.00
7/8/2025	COGT Cogent Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
7/8/2025	COGT Cogent Biosciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
7/7/2025	COGT Cogent Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $28.00
7/7/2025	COGT Cogent Biosciences	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $18.00
6/30/2025	COGT Cogent Biosciences	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral	$10.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/26/2025	EPRX Eupraxia Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$12.00
6/17/2025	COGT Cogent Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/16/2025	EPRX Eupraxia Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Speculative Buy

(Data available from 7/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$1.32 per share	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	$9.04M	80.85	N/A	N/A	$2.27 per share	3.70
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	$7.42 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
COGT Cogent Biosciences	-$255.86M	-$1.84	N/A	N/A	N/A	N/A	-149.79%	-75.61%	8/5/2025 (Estimated)
EPRX Eupraxia Pharmaceuticals	-$25.50M	-$0.76	N/A	N/A	N/A	N/A	-367.73%	-112.23%	8/6/2025 (Estimated)
IMNM Immunome	-$292.96M	-$3.18	N/A	N/A	N/A	-1,875.21%	-71.65%	-60.36%	8/11/2025 (Estimated)
LENZ LENZ Therapeutics	-$49.77M	-$1.77	N/A	N/A	N/A	N/A	-23.74%	-22.65%	8/13/2025 (Estimated)

Latest EPRX, LENZ, COGT, and IMNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2025	Q2 2025	LENZ LENZ Therapeutics	-$0.62	N/A	N/A	N/A	N/A	N/A
8/11/2025	Q2 2025	IMNM Immunome	-$0.52	N/A	N/A	N/A	$1.03 million	N/A
8/6/2025	N/A	EPRX Eupraxia Pharmaceuticals	-$0.21	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	COGT Cogent Biosciences	-$0.54	N/A	N/A	N/A	N/A	N/A
5/12/2025	Q1 2025	IMNM Immunome	-$0.66	-$0.52	+$0.14	-$0.52	$0.46 million	$2.93 million
5/7/2025	Q1 2025	LENZ LENZ Therapeutics	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A
5/6/2025	Q1 2025	COGT Cogent Biosciences	-$0.56	-$0.52	+$0.04	-$0.52	N/A	N/A
5/6/2025	Q1 2025	EPRX Eupraxia Pharmaceuticals	-$0.19	-$0.21	-$0.02	-$0.21	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
EPRX Eupraxia Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
IMNM Immunome	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
COGT Cogent Biosciences	N/A	5.13	5.13
EPRX Eupraxia Pharmaceuticals	N/A	11.10	11.10
IMNM Immunome	N/A	10.49	10.49
LENZ LENZ Therapeutics	N/A	23.09	23.09

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
COGT Cogent Biosciences	N/A
EPRX Eupraxia Pharmaceuticals	N/A
IMNM Immunome	44.58%
LENZ LENZ Therapeutics	54.32%

Insider Ownership

Company	Insider Ownership
COGT Cogent Biosciences	7.29%
EPRX Eupraxia Pharmaceuticals	N/A
IMNM Immunome	8.60%
LENZ LENZ Therapeutics	6.90%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
COGT Cogent Biosciences	80	113.86 million	105.56 million	Optionable
EPRX Eupraxia Pharmaceuticals	29	35.96 million	N/A	N/A
IMNM Immunome	40	87.01 million	79.53 million	Optionable
LENZ LENZ Therapeutics	110	28.15 million	26.20 million	N/A

EPRX, LENZ, COGT, and IMNM Headlines

Recent News About These Companies

FY2028 Earnings Estimate for LENZ Issued By Leerink Partnrs

July 14 at 2:13 AM | americanbankingnews.com

Leerink Partnrs Has Bearish Outlook for LENZ FY2028 Earnings

July 14 at 2:11 AM | marketbeat.com

LENZ Therapeutics (NASDAQ:LENZ) Stock Price Down 5.9% - Should You Sell?

July 10, 2025 | marketbeat.com

LENZ Therapeutics (NASDAQ:LENZ) Trading Up 8.7% - What's Next?

July 9, 2025 | marketbeat.com

LENZ Therapeutics and Laboratoires Théa partner to commercialize LNZ100 for presbyopia in Canada

July 9, 2025 | ophthalmologytimes.comO

LENZ Therapeutics and Laboratoires Théa Announce Exclusive License and Commercialization Agreement for LNZ100 in Canada

July 7, 2025 | globenewswire.com

LENZ Therapeutics: Presbyopia Eyedrops Look Promising

July 1, 2025 | seekingalpha.com

LENZ Therapeutics Inc Dividends - Morningstar

July 1, 2025 | morningstar.comM

Lisanti Capital Growth LLC Purchases New Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ)

June 30, 2025 | marketbeat.com

LENZ - LENZ Therapeutics Inc Trailing Returns - Morningstar

June 28, 2025 | morningstar.comM

LENZ Therapeutics Inc Financials - Morningstar

June 27, 2025 | morningstar.comM

LENZ Therapeutics, Inc. (NASDAQ:LENZ) Given Average Rating of "Buy" by Brokerages

June 26, 2025 | marketbeat.com

Versant sells LENZ therapeutics (LENZ) stock worth $10.1 million

June 22, 2025 | investing.com

LENZ Therapeutics: Ready To Test Its Potential

June 16, 2025 | seekingalpha.com

Healthcare companies chase cures and capital in South Florida

June 11, 2025 | sun-sentinel.comS

LENZ Therapeutics May 2025 slides: presbyopia treatment nears FDA decision

May 29, 2025 | uk.investing.com

LENZ Therapeutics to Present at Upcoming Investor Conferences

May 27, 2025 | manilatimes.netM

LENZ and Lotus Pharmaceutical collaborate to commercialise presbyopia treatment

May 12, 2025 | msn.com

LENZ Therapeutics, Inc. (LENZ) Q1 2025 Earnings Call Transcript

May 11, 2025 | seekingalpha.com

Earnings call transcript: LENZ Therapeutics’ Q1 2025 results show innovation drive

May 9, 2025 | uk.investing.com

LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia

May 9, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

EPRX, LENZ, COGT, and IMNM Company Descriptions

Cogent Biosciences NASDAQ:COGT

$11.50 +0.41 (+3.70%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$11.52 +0.02 (+0.17%)

As of 07:04 AM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Eupraxia Pharmaceuticals NASDAQ:EPRX

$5.35 -0.24 (-4.31%)

Closing price 07/15/2025 03:55 PM Eastern

Extended Trading

$5.69 +0.34 (+6.36%)

As of 07/15/2025 07:18 PM Eastern

Eupraxia Pharmaceuticals Inc. is a clinical-stage biotechnology company. It focused on the development of locally delivered, extended-release products that have the potential to address therapeutic areas with high unmet medical need. Th company's lead product candidate includes EP-104IAR, for the treatment of pain due to osteoarthritis of the knee. Eupraxia Pharmaceuticals Inc. is based in VICTORIA, BC.

Immunome NASDAQ:IMNM

$8.40 -0.11 (-1.29%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$8.40 +0.00 (+0.06%)

As of 07/15/2025 07:45 PM Eastern

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

LENZ Therapeutics NASDAQ:LENZ

$32.75 -0.98 (-2.91%)

Closing price 07/15/2025 04:00 PM Eastern

Extended Trading

$34.12 +1.37 (+4.18%)

As of 07/15/2025 06:34 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time